Nuvectis Pharma (NVCT) Total Non-Current Liabilities (2021 - 2025)

Nuvectis Pharma (NVCT) has 5 years of Total Non-Current Liabilities data on file, last reported at $13.3 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities rose 49.49% year-over-year to $13.3 million; the trailing twelve-month figure through Dec 2025 stood at $13.3 million (up 49.49% YoY), and the FY2025 full-year result was $13.3 million, up 49.49% from the prior year.
• Total Non-Current Liabilities improved to $13.3 million in Q4 2025, from $8.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $13.3 million in Q4 2025 to a low of -$12.8 million in Q4 2021.
• A 5-year average of $4.5 million and a median of $7.0 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities jumped 148.23% in 2022 and rose 12.9% in 2023, its largest moves.
• Tracing NVCT's Total Non-Current Liabilities over 5 years: stood at -$12.8 million in 2021, then jumped by 148.23% to $6.2 million in 2022, then increased by 12.9% to $7.0 million in 2023, then increased by 27.35% to $8.9 million in 2024, then jumped by 49.49% to $13.3 million in 2025.
• Business Quant data shows NVCT's Total Non-Current Liabilities at $13.3 million in Q4 2025, $8.9 million in Q4 2024, and $7.0 million in Q4 2023.